• The Series B funding will back Exciva’s Phase 2 clinical trial of its lead drug candidate, Deraphan, targeting agitation linked to Alzheimer’s disease (AD)
• The funding round was co-led by EQT Life Sciences (from its LSP Dementia Fund) and Gimv, with contributions from Fountain Healthcare Partners, LifeArc, Carma Fund, Modi Ventures, plus returning investors Andera Partners and LBBW
• This investment highlights EQT Life Sciences’ dedication to high-impact neuroscience treatments and will help Exciva work toward meeting a major unmet need in Alzheimer’s care

STOCKHOLM, Jan. 20, 2026 — EQT Life Sciences is happy to share that its LSP Dementia Fund has co-led a EUR 51 million Series B funding round for Exciva (the “Company”), a clinical-stage biopharma firm focused on creating new treatments for behavioral symptoms linked to Alzheimer’s disease (AD).

Neuropsychiatric symptoms like agitation and other behavioral issues impact up to 90% of patients with severe AD, increasing caregiver stress, healthcare usage, and lowering quality of life. Even though this challenge is large—made worse by the world’s aging population—therapeutic innovation has fallen behind. The Series B funding will back Exciva’s Phase 2 trial of Deraphan, the company’s lead drug candidate for AD-related agitation. This trial will take place in the EU, U.S., and Canada.

Exciva’s strategy is based on solid scientific and clinical groundwork. Deraphan— a mix of two clinically approved compounds (one being a new chemical entity)—has shown positive safety and tolerability in Phase 1 trials. It also has the potential to deliver a distinct efficacy and safety profile compared to existing treatments, which are often held back by boxed warnings, side effects, or inconsistent results.

François Conquet, Exciva’s CEO, stated: “We’re thrilled to have secured funding from both new and returning investors—this reinforces our confidence in our drug candidate’s promise. Positive Phase 2 trial results would mark a major milestone in symptomatic treatment options for AD patients.”

Philip Scheltens, MD, PhD, Partner at EQT Life Sciences, commented: “This investment shows Exciva’s ability to bring exciting innovation to a field where Alzheimer’s patients have few or no treatment choices. We’re happy to co-lead this funding round to help unlock Exciva’s potential—what sets the company apart is both its high-quality science and the expertise of its team. We can’t wait to bring this innovation to patients.”

After the investment, EQT Life Sciences will have Philip Scheltens as a Director and Juliette Lee as an Observer on Exciva’s Board.

Contact
EQT Press Office,

This information is provided by Cision .

The following files are available for download: